Elevance Health reports Q2 2026: Revenue $49.8B, Adj. diluted EPS $7.45, raises FY guidance
I'm LongbridgeAI, I can summarize articles.Elevance Health reported Q2 2026 revenue of $49.8B and adjusted diluted EPS of $7.45, raising full-year guidance to at least $20.10 diluted and $27.00 adjusted EPS. The company cited favorable benefit expenses and below-the-line benefits. Management plans to accelerate investments in capabilities to lower healthcare costs and strengthen Carelon's integrated solutions.
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion and shareholders' diluted EPS of $6.71, with adjusted diluted EPS of $7.45. The company raised full-year 2026 guidance to at least $20.10 diluted EPS and at least $27.00 adjusted diluted EPS, citing favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit in the quarter. Management said it will accelerate targeted investments in capabilities to lower healthcare costs, simplify member/provider experience and strengthen Carelon's integrated solutions.
Financial Highlights
- Total operating revenue: $49.8 billion for Q2 2026, up 0.8% year over year.
- Operating gain (total): $1.8 billion for Q2 2026; operating margin 3.5% (Q2 2026).
- Net income (shareholders' net income): $1,463 million for Q2 2026; diluted EPS $6.71.
- Adjusted shareholders' earnings per diluted share: $7.45 for Q2 2026; adjusted shareholders' net income $1,624 million.
- Raised full-year 2026 outlook: diluted EPS at least $20.10 and adjusted diluted EPS at least $27.00; operating cash flow guidance raised to at least $6.0 billion.
Business Highlights
- Health Benefits segment operating revenue: $42.7 billion in Q2 2026, up 2.7% year over year; operating gain decreased to $896 million as benefit expense and targeted investments increased.
- Carelon (CarelonRx and Carelon Services) operating revenue scaled to $19.2 billion combined for Q2 2026, driven by Carelon Services risk-based solutions and CarelonRx product growth.
- Medical membership totaled approximately 44.9 million as of June 30, 2026, down 469,000 sequentially due to a commercial fee-based customer transition and anticipated ACA and Medicaid attrition.
- Benefit expense ratio was 89.7% in the quarter (up 80 basis points year over year) reflecting elevated medical cost trends in Government businesses offset in part by improved Individual ACA performance.
- Operational metrics: days in claims payable were 45.4 days (up 2.9 days year over year); CarelonRx quarterly adjusted scripts ~80.9 million and Carelon Services consumers served ~92.4 million.
Original SEC Filing: Elevance Health, Inc. [ ELV ] - 8-K - Jul. 15, 2026